📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
1 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
NEUTRAL
TOTAL VIEWS
16
PALI Latest News & AI Sentiment Analysis
1 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 3 ARTICLES
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Palisade Bio (PALI) disclosed routine Q2 2026 financial results alongside clinical development updates for its lead candidate PALI-2108,...
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio (PALI) announced participation in the Leerink Partners Therapeutics Forum, a standard investor engagement event scheduled...
Palisade Bio Stock: A Unique MoA Targeting The UC And Crohn’s Disease Markets (PALI)
Palisade Bio (PALI) has disclosed Phase 1 safety data for its experimental therapeutic PALI-2108, designed to address inflammatory bowel...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice